Short Term Outlook For Novavax, Inc. (NASDAQ:NVAX)

Lloyd Doyle
November 22, 2017

Further, company shares have been seen trading -20.79% off of the 52 week high and 93.15% away from the 52 week low.

Viewray Inc Cm ST (NASDAQ:VRAY) shares traded up 0.65% during most recent session. The firm is scheduled to report its next earnings results on Monday, February 26th. During the same quarter in the prior year, the company earned ($0.24) EPS. equities research analysts predict that Novavax will post -0.62 EPS for the current year. Earnings, with 7 analysts believing the company would generate an Average Estimate of $-0.16. The mean target projections are based on 5 opinions.

Novavax, Inc. (NASDAQ:NVAX) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent.

Model N, Inc. has a consensus outperform rating from 6 Wall Street analysts, and the number of shares now sold short amount to at least 3.86% of shares outstanding. The business had revenue of $8.35 million during the quarter, compared to analysts' expectations of $6.42 million. The business's revenue was up 158.5% on a year-over-year basis. For the quarter, shares are performing at -43.52%.


NVAX has been the topic of a number of analyst reports. BidaskClub lowered Novavax from a "hold" rating to a "sell" rating in a research report on Saturday, August 5th.

The consensus recommendation, according to Zacks Investment research, is 2.43. Citigroup Inc. raised Novavax from a "neutral" rating to a "buy" rating and set a $2.00 price objective for the company in a research report on Tuesday, October 31st. Analysts reported that the Price Target for Novavax, Inc. might touch $2 high while the Average Price Target and Low price Target is $1.64 and $1.5 respectively.

November 8 investment analysts at Cantor Fitzgerald kept the company rating at "Hold" projecting a price of $2.00. The stock presently has a consensus rating of "Hold" and an average target price of $3.12. Has $537,000 Position in Novavax, Inc. During the same quarter past year, the firm posted ($0.24) earnings per share. If you are reading this article on another site, it was copied illegally and republished in violation of global trademark & copyright law. (NASDAQ:NVAX), its shares were trading at $1.41 a gain of $0.05, on the trading floor. The investor is now holding 6,198,341 shares thanks to an increase of 1,001,833 new shares in their portfolio. The High end of the Estimate is $10.3 Million, while the Low end of the Estimate is $6 Million. Also, insider Stanley C. Erck acquired 100,000 shares of the company's stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $1.13 per share, with a total value of $113,000.00. The Manufacturers Life Insurance Company now owns 232,406 shares of the biopharmaceutical company's stock worth $267,000 after buying an additional 14,114 shares during the period. James F. Young, Director disclosed the sale of 175,000 shares of (NVAX). The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. Corporate insiders own 4.00% of the company's stock. (NASDAQ:NVAX) by 35.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The value of the investment in NVAX decreased from $51,000 to $41,000 a change of 19.6% since the last quarter. HighTower Advisors LLC grew its stake in shares of Novavax by 3.8% during the 1st quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company's stock valued at $184,000 after purchasing an additional 5,250 shares during the period. Finally, Nationwide Fund Advisors grew its stake in Novavax by 555.1% in the 2nd quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company's stock worth $3,883,000 after acquiring an additional 92,854 shares during the period.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER